Phase I Study to Investigate Safety, Pharmacokinetics and Preliminary Efficacy Profile of Sorafenib (BAY 43-9006) in Combination With S-1 Plus CDDP in Asian Patients With Unresectable / Recurrent Gastric Cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2012
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
- Indications Gastric cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 30 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 20 Nov 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.